SCHEMBL22845379

SCHEMBL22845379

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(NCc5ccccc5)c24)CN(C(=O)c2ccc(Cl)c(Cl)c2)CC3)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PREP P48147 1/20 0.36
LMNA P02545 5/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 1/20 0.36
HTT P42858 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM1 Q13255 4/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PRLHR P49683 2/20 0.35
POLB P06746 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
BRD4 O60885 1/20 0.35
KAT2B Q92831 1/20 0.35
BRD9 Q9H8M2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845388 0.94 PREP (0.35) PREPSMN1; SMN2GRM1PRLHRHDAC1
SCHEMBL22845368 0.93 PREP (0.40) PREPLMNAMAPTALDH1A1GAA
SCHEMBL22845341 0.91 PREP (0.37) PREPLMNAMAPTALDH1A1GAA
SCHEMBL22845418 0.91 PRLHR (0.34) GRM1PRLHR
SCHEMBL22845325 0.91 MAPT (0.41) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL22845199 0.90 LMNA (0.37) LMNAMAPTALDH1A1GAAHTT
SCHEMBL22845518 0.89 PRLHR (0.35) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL22845208 0.89 PRLHR (0.35) LMNAMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL22845294 0.89 PRLHR (0.37) MAPTPRLHRPOLB
SCHEMBL22845519 0.89 MTHFD2 (0.35) LMNAMAPTALDH1A1GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL PREP 966/4885LMNA 1680/4885MAPT 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.